Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C). Prolongation of disease‐free interval and survival

Giora M. Mavligit, Jordan U. Gutterman, Mary Anne Malahy, Michael A. Burgess, Charles M. McBride, Andre Jubert, Evan M. Hersh

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

The poor postsurgical prognosis in patients with colorectal cancer of the Dukes' C classification has prompted a clinical trial of adjuvant immunotherapy versus chemoimmunotherapy intended to prolong either the disease‐free interval or the overall survival or both. One hundred and twenty‐one patients have been entered on this study. Fifty‐two patients received BCG alone and 69 patients received the combination of 5‐FU and BCG. The disease‐free interval and the overall survival were compared with similar parameters in a group of historical controls with similar prognostic characteristics who were operated on in our institution prior to the initiation of the current study. There was no difference as yet between BCG alone and the combination of 5‐FU + BCG in terms of both the disease‐free interval and the survival. Both treatments, however, had significantly better results than the surgical controls. Adjuvant therapy, especially with BCG is advocated for patients with colorectal carcinoma, Dukes' C class, following potentially curative surgery.

Original languageEnglish (US)
Pages (from-to)2726-2730
Number of pages5
JournalCancer
Volume40
Issue number5 S
DOIs
StatePublished - Nov 1977

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C). Prolongation of disease‐free interval and survival'. Together they form a unique fingerprint.

  • Cite this